Meine Merkliste  

2.659 Aktuelle Fachpublikationen von Future Medicine


Genomic architecture of pharmacological efficacy and adverse events

18.12.2014 | Aparna Chhibber; Deanna L Kroetz; Kelan G Tantisira; Michael McGeachie; Cheng Cheng; Robert Plenge; Eli Stahl; Wolfg ..., Pharmacogenomics, 2014

The pharmacokinetic and pharmacodynamic disciplines address pharmacological traits, including efficacy and adverse events. Pharmacogenomics studies have identified pervasive genetic effects on treatment outcomes, resulting in the development of genetic biomarkers for optimization of drug therapy. ...


Exploiting combinatorial patterns in cancer genomic data for personalized therapy and new target discovery

18.12.2014 | Michael Schubert; Francesco Iorio, Pharmacogenomics, 2014

Pharmacogenomics December 2014, Vol. 15, No. 16, Pages 1943-1946.


Donor ABCB1 genetic polymorphisms influence epithelial-to-mesenchyme transition in tacrolimus-treated kidney recipients

18.12.2014 | Julie Bloch; Marc Hazzan; Cynthia Van der Hauwaert; David Buob; Grégoire Savary; Alexandre Hertig; Viviane Gnemmi; M ..., Pharmacogenomics, 2014

Aim: The contribution of epithelial–mesenchymal transition (EMT) has been suggested in renal transplant recipients receiving calcineurin inhibitors and developing nephrotoxicity. Materials & methods: We assessed whether interindividual variability in tacrolimus pharmacokinetics is associated with ...


Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors

18.12.2014 | David Della-Morte; Raffaele Palmirotta; Ashish K Rehni; Donatella Pastore; Barbara Capuani; Francesca Pacifici; Mari ..., Pharmacogenomics, 2014

The most important goal in the treatment of patients with diabetes is to prevent the risk of cardiovascular disease (CVD), the first cause of mortality in these subjects. Thiazolidinediones (TZDs), a class of antidiabetic drugs, act as insulin sensitizers increasing insulin-dependent glucose ...


Pharmacogenetics of inflammatory bowel disease

18.12.2014 | Konstantinos H Katsanos; Konstantinos A Papadakis, Pharmacogenomics, 2014

Pharmacogenetic studies have been performed for almost all classes of drugs that have been used in IBD but very few have generated consistent findings or have been replicated. The genetic test that has been approved for clinical practice is TPMT testing prior to starting treatment with thiopurine ...


Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics

18.12.2014 | Jessica Tay-Sontheimer; Laura M Shireman; Richard P Beyer; Taurence Senn; Daniela Witten; Robin E Pearce; Andrea Gae ..., Pharmacogenomics, 2014

Aim: We sought to discover endogenous urinary biomarkers of human CYP2D6 activity. Patients & methods: Healthy pediatric subjects (n = 189) were phenotyped using dextromethorphan and randomized for candidate biomarker selection and validation. Global urinary metabolomics was performed using ...


Dopaminergic pathway polymorphisms and heroin addiction: further support for association of CSNK1E variants

18.12.2014 | Orna Levran; Einat Peles; Matthew Randesi; Joel Correa da Rosa; Jurg Ott; John Rotrosen; Miriam Adelson; Mary Jeanne ..., Pharmacogenomics, 2014

Background & aim: The dopaminergic pathways have been implicated in the etiology of drug addictions. The aim of this study was to determine if variants in dopaminergic genes are associated with heroin addiction. Materials & methods: The study includes 828 former heroin addicts and 232 healthy ...


POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia

18.12.2014 | Euridiki Drogari; Georgia Ragia; Vasiliki Mollaki; Laure Elens; Ron HN Van Schaik; Vangelis G Manolopoulos, Pharmacogenomics, 2014

Background: In children and adolescents with familial hypercholesterolemia (FH) pharmacotherapy with statins is the cornerstone in the current regimen to reduce low-density lipoprotein cholesterol (LDLc) and premature coronary heart disease risk. There is, however, a great interindividual ...


Hepatitis E in developed countries: current status and future perspectives

17.12.2014 | Harry R Dalton; Nassim Kamar; Jacques Izopet, Future Microbiology, 2014

ABSTRACT  Hepatitis E virus (HEV) was for many years thought to be found almost exclusively in developing countries, where it is a major health issue. Recent studies have shown that HEV causes acute and chronic infection in developed countries. In these geographical settings, HEV is primarily a ...


Filamentous hemagglutinin of Bordetella pertussis: a key adhesin with immunomodulatory properties?

17.12.2014 | Rodrigo Villarino Romero; Radim Osicka; Peter Sebo, Future Microbiology, 2014

ABSTRACT  The filamentous hemagglutinin of pathogenic Bordetellae is a prototype of a large two-partner-system-secreted and β-structure-rich bacterial adhesin. It exhibits several binding activities that may facilitate bacterial adherence to airway mucosa and host phagocytes in the initial phases ...


Seite 2 von 266
Suche per e-Mail abonnieren

Sie erhalten passend zu Ihrer Suche die neusten Suchergebnisse per E-Mail. Dieser Service ist für Sie kostenlos und kann jederzeit abbestellt werden.

Ihr Bowser ist nicht aktuell. Microsoft Internet Explorer 6.0 unterstützt einige Funktionen auf Chemie.DE nicht.